Cancer Chemotherapy and Pharmacology

, Volume 20, Issue 3, pp 265–266 | Cite as

High-dose VP-16 with intermediate-dose cytosine arabinoside in the treatment of relapsed acute nonlymphocytic leukemia

  • Hon Y. Chan
  • Frederick J. Meyers
  • Jerry P. Lewis
Short Communication VP-16, Cytosine Arabinoside, Nonlymphocytic Leukaemia

Summary

In a study of 11 adult patients with acute nonlymphocytic leukemia (ANLL), infusion therapy with high-dose VP-16 and intermediate-dose cytosine arabinoside was administered. Response was assessed with reference to bone marrow aspirations performed on days 1; 12, 13, or 14; and 21 of treatment. All 7 of the patients with ANLL in relapse achieved marrow hypoplasia, and 3 of them achieved complete response. LFTs were elevated in most patients but no evidence of hepatocellular necrosis was observed. It is concluded that the value of VP-16 in ANLL may have been underestimated in the past because of inadequate dosing.

Keywords

Bone Marrow Leukemia Cancer Research Adult Patient Cytosine 

Abbreviations

ANLL

acute nonlymphocytic leukemia

CGL

chronic granulocytic leukemia

DNR

daunorubicin

VNC

vincristine

ID

Ara-C, intermediate-dose Ara-C (500 mg/m2 for 12 doses)

HD

Ara-C, high-dose Ara-C (3 g/m2 for 12 doses)

SGGT

serum glutamic transaminase

LDH

lactic dehydrogenase

SGOT

serum glutamic oxaloacetic transaminase

References

  1. 1.
    Herzig RH, Hillard ML, Wolff SN, Phillips GL, Herzig GP (1985) High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol 3 (7): 992Google Scholar
  2. 2.
    Lewis JP (1985) Clinical trials of adult acute nonlymphocytic leukemia: evidence of progress. Cancer Treat Rev 12: 133–143Google Scholar
  3. 3.
    Postmus PE, Mulder NH, Sleijfer DT, Meinesz AF, Vriesendorp R, DeVries DGE (1984) High-dose etoposide for refractory malignancies: a phase I study. Cancer Treat Rep 68 (12): 1471Google Scholar
  4. 4.
    Preisler HD (1982) Treatment failure in AML. Blood Cells 8: 585–602Google Scholar
  5. 5.
    van Prooijen HC, Dekker AW, Punt K (1984) The use of intermediate dose cytosine arabinoside (ID Ara-C) in the treatment of acute non-lymphocytic leukaemia in relapse. Br J Haematol 57: 291–299Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Hon Y. Chan
    • 1
  • Frederick J. Meyers
    • 1
  • Jerry P. Lewis
    • 1
  1. 1.Department of Internal Medicine, Division of Hematology and OncologyUniversity of California, Davis Medical CenterSacramentoUSA

Personalised recommendations